CCR5 and HIV Infection, a View from Brussels by Marc Parmentier
OPINION ARTICLE
published: 08 June 2015
doi: 10.3389/fimmu.2015.00295
CCR5 and HIV infection, a view from Brussels
Marc Parmentier*
Welbio and IRIBHM, Université Libre de Bruxelles, Brussels, Belgium
*Correspondence: mparment@ulb.ac.be
Edited by:
Bernhard Moser, Cardiff University, UK
Reviewed by:
Alexandra Trkola, University of Zurich, Switzerland
Keywords: G protein-coupled receptors, chemokines, human immunodeficiency virus, CCR5, gene variants
HIV co-receptors were quite far from our
main interests at the end of 1995, and we
got involved in this field in a totally unex-
pected way. Our interest in chemokines was
even relatively new at that moment, as we
were mostly dealing with the characteri-
zation of new G protein-coupled recep-
tors (GPCRs) in various areas such as
endocrinology, neuroscience, and olfac-
tion. Candidate receptors for leukocyte
chemoattractant factors were part of an
expanding repertoire of “orphan” recep-
tors under study. I will essentially describe
here a relatively short period of years 1995–
1996, which has been one of the most
hectic in my scientific career. This period
is viewed from our perspective in Brus-
sels, as I do not know for sure what was
going on in other laboratories around the
world, besides the results of these activities
in terms of publications, communications
in meetings, or personal contacts. I apolo-
gize in advance for the unavoidable bias in
this sort of “historical” review.
A few years earlier, in the end of 1980s,
our Institute had a strong focus on thyroid
research. The most dynamic part of this
activity was the cloning of some of the main
actors of thyroid hormone biosynthesis, the
hormone precursor thyroglobulin and the
iodinating enzyme thyroperoxidase. A pri-
mary objective at that time was the cloning
of the main regulator of thyroid function,
the thyrotropin receptor, which was known
as coupled to the stimulation of adeny-
late cyclase through the Gs protein. It is
the search for the thyrotropin receptor that
ultimately led, amongst many other unex-
pected findings, to our contribution to the
characterization of CCR5 and its role in
HIV infection.
G protein-coupled receptors constitute
the largest family of membrane recep-
tors and collectively play a major role
in all physiological and pathophysiolog-
ical processes. GPCRs share a common
structural organization with seven trans-
membrane segments, and a common way
of modulating cell functions by regulating
effector systems through heterotrimeric G
proteins and arrestins. The first GPCR
sequences (rhodopsin, β-adrenergic, and
M1 muscarinic receptors) were obtained
in 1986–1988, following protein purifica-
tion and peptide sequencing approaches.
As a result, the common transmembrane
organization and structural relatedness of
GPCRs became obvious. Gilbert Vassart,
leading the molecular biology group of
the Institute, suggested applying the newly
developed PCR method to the search of
new members of the GPCR family, by using
degenerate primers corresponding to the
most conserved motifs among the small
number of available GPCR sequences. A
Ph.D. student in the Institute, Frédérick
Libert, set up the procedure very success-
fully, and cloned within a few weeks, four
new members of the GPCR family, that
were referred to as “orphan” receptors (1).
These were later characterized as CXCR7,
serotonin 5HT1Dα, and adenosine A1 and
A2a receptors. In the aftermath, a bunch of
other orphan receptors were cloned, and we
characterized the target of this new cloning
strategy, the thyrotropin receptor (2). This
PCR cloning approach, used first in Brus-
sels, was applied broadly by other labs after-
wards, and contributed significantly to the
vigorous reporting of new GPCRs in the
early 1990s.
In our hands, the first CCR5 sequences
originated from a screen performed by
Catherine Mollereau in early 1993 with
the aim of identifying subtypes of opioid
receptors. This screen led among others
to the cloning of ORL1, a fourth mem-
ber of the opiate receptor family, and the
identification of its peptidic ligand noci-
ceptin (3). A number of partial sequences
were also similar to the first chemokine
receptors, CXCR1, CXCR2, and CCR1,
reported by the groups of Phil Murphy
and Tom Schall (4, 5). We thus decided
to engage into the functional charac-
terization of these candidate chemokine
receptors. The cDNA encoding CCR5 was
expressed in CHO-K1 cells and tested in
a microphysiometer, an ancestor of the
“label free” instruments, which measured
changes in cell metabolism by monitor-
ing the acidification rate of the culture
medium. MIP-1α/CCL3, MIP-1β/CCL4,
and RANTES/CCL5 were identified by a
French post-doc, Michel Samson, as three
chemokines able to activate the recep-
tor. The manuscript was first submitted
to JBC in early September 1995, but was
rejected after a 3-month reviewing process.
It was resubmitted to Biochemistry in
December (6).
In the meantime, a paper was published
in December 1995 by the group of Paolo
Lusso and Robert Gallo (7), describing
that three chemokines, MIP-1α, MIP-1β,
and RANTES, were able to inhibit infec-
tion of cells by macrophage-tropic HIV-
1 strains. The link between the pharma-
cology of CCR5 and the profile of HIV
inhibitory factors was of course striking.
With no tools at hand for studying HIV, we
first mailed Robert Gallo in January 1996
to propose some kind of collaboration to
study the role of CCR5 in HIV infection.
We never got an answer to this letter. It was
quite clear at that time that we were not
the only group to have CCR5 on hands.
There were a bunch of very active groups in
the chemokine receptor field, such as those
of Philip Murphy, Craig Gerard, and Tom
Schall. CCR3 and CCR4 had been pub-
lished in late 1995 and Phil Murphy had
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FIGURE 1 |The transmembrane organization of CCR5 is
represented with its seven transmembrane segments, the eighth
α-helix parallel to the plasma membrane, the two disulfide bonds,
and the palmitoylated cysteines. The position of some of the variants
demonstrated to affect CCR5 function is indicated. The ∆32 mutant,
with an average allele frequency of about 10% in European populations
is the most frequent. Two missense mutations (C20S and C178R) affect
one of the disulfide bonds necessary for the correct folding of the
receptor. Two other mutations (C101X and the frame shift mutant
FS299) result in early termination of translation. None of these mutant
receptors is properly expressed at the surface of cells. Besides ∆32,
the most frequent mutation is FS299, with an allele frequency of 2.9%
in Chinese subpopulations. The allele frequencies of other mutations
are well below 1%.
reported the CCR3 sequence with MIP-1α,
MIP-1β, and RANTES as agonists. This was
later retracted as a result of a clone handling
mistake, but it was quite clear that CCR5
and its pharmacology were in other hands
as well.
While considering other potential col-
laborators, our manuscript dealing with
CCR5 pharmacology became available, and
very rapidly afterwards, I got a mail from
Bob Doms in Philadelphia, proposing to
join efforts on this topic. We sent to Bob
plasmids encoding CCR5 and a set of
related receptors we had at that time. Bob
was obviously not alone in this game. In the
HIV community, the existence of an HIV
co-receptor, the orphan GPCR LESTR (and
future CXCR4), for T-tropic HIV strains
was already well known. The data would
appear 1 month later in an April issue of
Science (8). Many HIV groups were there-
fore looking for other GPCRs that would
mediate the entry of HIV in macrophages
and got in touch with teams involved in
the chemokine receptor field. The race was
fierce, and five papers reporting CCR5 as
HIV co-receptor were published within a
week in Nature, Cell, and Science in June
1996 (9–13). As a measure of the rush that
took place in editorial offices and printing
houses,our common paper with Bob Doms
submitted on June 10 was published by
Cell on June 28 with several pages printed
upside down.
CCR5 seemed to play a key role in
the entry of HIV strains involved in dis-
ease transmission. Soon after the first feed-
back by Bob Doms of the experiments
performed in Philadelphia, Gilbert Vas-
sart suggested to check whether variants
of CCR5 could be responsible for the
variable susceptibility to HIV infection.
We first obtained from a clinician of the
nearby hospital, Claire Farber, DNA sam-
ples from three patients with slow dis-
ease progression and a few uninfected con-
trols. Unexpectedly, Frédérick Libert and
Michel Samson identified in this small
series one slow progressor but also two
control individuals as heterozygous for the
same mutation of CCR5, a 32-base pair
deletion in a region corresponding to the
second extracellular loop of the receptor,
and resulting in a frame shift and early
termination (Figure 1). This mutant form
of the CCR5 gene did not explain the
slow progression of the patients tested.
It was clear however that the resulting
CCR5 mutant could not act as a func-
tional receptor, and that the mutant allele
was quite frequent. Within days, we sent
a plasmid encoding this CCR5 mutant
to Bob Doms for testing its function as
HIV co-receptor, initiated experiments to
demonstrate its deficiency as a chemokine
receptor, and started collecting samples to
study the frequency of the mutation at a
larger scale. There were well-established
cohorts of uninfected but multiply exposed
individuals, but a few phone calls sug-
gested to us that obtaining the genomic
DNA from these cohorts would take ages
compared to the pace at which this field
was developing. We opted therefore for a
more accessible approach. Starting from
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our local contacts in the campus hospi-
tal, were gathered within a week from
various hospitals in Belgium and France,
collections of DNA samples from cohorts
of HIV-infected patients and uninfected
controls, reasoning that the frequency of
the mutant CCR5 allele should be dif-
ferent between these two groups if this
allele was protective against HIV infec-
tion. We also collected DNA samples from
about a hundred volunteers in the Insti-
tute’s staff. Testing these samples as they
arrived builded progressively what is now
known as the allele frequency of the ∆32
allele, around 10% in Western Europe.
More importantly, while the number of
homozygotes was in the expected range for
Mendelian distribution in the uninfected
group, there was a lack of homozygotes in
the HIV-infected group. When each group
reached over 700 individuals, the p value
was below 0.0005. In the meantime, we
had also found three ∆32 homozygotes
within the institute personnel. We could
rush blood cells to our Philadelphia collab-
orators to check whether these cells were
indeed resistant to macrophage-tropic, but
not T-tropic HIV-1 strains. This was indeed
the case.
The manuscript was submitted to
Nature in mid-July 1996. Although there
was a strong interest of the Editor, one of
the referees opposed us the fact that our
cohorts were not constructed according to
the rules. While we quite agreed on this,
we had to fight to convince the editor that
the data were clear enough to overcome
weaknesses in cohort structure, and that
there was no time to be spent on theo-
retical considerations. The final argument
came when we could state that a concur-
rent manuscript had been submitted to Cell
by the Ned Landau group and that it was
being reviewed positively. As a result, we
were requested to respond to the latest ref-
eree comments by correcting the text at the
proof stage, and the two papers appeared
in August 1996 (14, 15).
It was shown later on by various groups
that protection by the ∆32 allele was
not complete, and a few infected ∆32
homozygotes have been reported within
the following years. In the following
months and years, we have studied the
structure–function relationships of CCR5
in relation to its role of chemokine recep-
tor and HIV co-receptor, analyzed the
distribution of the ∆32 mutation in var-
ious populations of the world, and tested
the functional consequences of other, less
frequent, variants and mutants of CCR5
(Figure 1). But somehow, the excitement
was over, and subsequent research became
more “routine.” The characterization of
the CCR5 ∆32 mutation and its conse-
quences on infection rate by HIV had
validated CCR5 as an obvious target for
the development of drugs targeting CCR5
and the entry of macrophage-tropic HIV
strains. Many pharmaceutical companies,
including Takeda, Pfizer, GSK, and Scher-
ing Plough, started immediately screening
programs that resulted a few years later
into CCR5 antagonists. While Takeda’s
TAK779, GSK’s aplaviroc, and Schering
Plough’s vicriviroc failed in clinical tri-
als for toxicity reasons, Pfizer’s maraviroc
went successfully through clinical testing
and was approved in 2007 as the first-
in-class CCR5 antagonist and HIV entry
inhibitor. Overall, this has been a very short
path (11 years altogether) between the dis-
covery of a target and the launch of a small
molecule in the clinics. With the present
availability of fast and efficient mutagen-
esis techniques such as the CRISPR/Cas9
system, gene therapy approaches for inac-
tivating CCR5 in the hematopoietic system
are also being considered actively for the
treatment of HIV infection.
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